和铂医药与Cullinan Oncology就B7H4x4-1BB双特异性抗体签订授权及合作协议
EQS 新闻 via SEAPRWire.com / 2023-02-14 / 11:12 UTC+8 和铂医药与Cullinan Oncology就B7H4x4-1BB双特异性抗体签订授权及合作协议 HBM7008是一款针对B7H4x...
Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC
SYDNEY, Sep 5, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology... » read more
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
SYDNEY, Jun 6, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, is sponsoring the Endpoints ASCO22 “Accelerating clinical development in China and the US”. Register here https://asco22.endpts.com/TUESDAY, JUNE 711:00am – 11:45am ET (1:00 – 1:45 local time)Novotech Booth at... » read more
Novotech Sponsors Pre-ASCO China Summit Expert Panels on Early Phase Oncology Trials and Regulatory Strategy for China and US
SYDNEY, Jun 2, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, has sponsored expert panels at the Pre-ASCO China Summit 2022 bringing together leaders in oncology drug development in China and the US. The Pre-ASCO series was watched by... » read more
Edison Oncology和冠科美博（Apollomics）宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Oct 1, 2021 – (亚太商讯 via SEAPRWire.com) – Edison...
Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 – (ACN Newswire via SEAPRWire.com) – Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, reported that... » read more
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors
FOSTER CITY, Calif. and HANGZHOU, China and MENLO PARK, CA, Feb 10, 2021 – (ACN Newswire) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Edison Oncology Holding Corp., today announced that Apollomics has been granted worldwide rights, excluding China, Hong Kong and Taiwan,... » read more
Sino Biopharmaceutical Announces 2020 Third Quarterly Results
HONG KONG, Nov 30, 2020 – (ACN Newswire) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2020 (the “review period”). During the review period,... » read more